| CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma B Coiffier, E Lepage, J Brière, R Herbrecht, H Tilly, R Bouabdallah, ... New England Journal of Medicine 346 (4), 235-242, 2002 | 6815 | 2002 |
| Follicular lymphoma international prognostic index P Solal-Céligny, P Roy, P Colombat, J White, JO Armitage, R Arranz-Saez, ... Blood 104 (5), 1258-1265, 2004 | 2147 | 2004 |
| Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte P Feugier, A Van Hoof, C Sebban, P Solal-Celigny, R Bouabdallah, ... Journal of clinical oncology 23 (18), 4117-4126, 2005 | 1902 | 2005 |
| Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe … B Coiffier, C Thieblemont, E Van Den Neste, G Lepeu, I Plantier, ... Blood, The Journal of the American Society of Hematology 116 (12), 2040-2045, 2010 | 1673 | 2010 |
| Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study B Coiffier, C Haioun, N Ketterer, A Engert, H Tilly, D Ma, P Johnson, ... Blood, The Journal of the American Society of Hematology 92 (6), 1927-1932, 1998 | 1303 | 1998 |
| Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial G Salles, JF Seymour, F Offner, A López-Guillermo, D Belada, L Xerri, ... The Lancet 377 (9759), 42-51, 2011 | 1246 | 2011 |
| Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up H Tilly, MG Da Silva, U Vitolo, A Jack, M Meignan, A Lopez-Guillermo, ... Annals of oncology 26, v116-v125, 2015 | 1082 | 2015 |
| TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis C Quivoron, L Couronné, V Della Valle, CK Lopez, I Plo, O Wagner-Ballon, ... Cancer cell 20 (1), 25-38, 2011 | 1014 | 2011 |
| Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des … P Brice, Y Bastion, E Lepage, N Brousse, C Haioun, P Moreau, ... Journal of Clinical Oncology 15 (3), 1110-1117, 1997 | 729 | 1997 |
| Rituximab plus CHOP (R-CHOP) overcomes bcl-2—associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL) N Mounier, J Briere, C Gisselbrecht, JF Emile, P Lederlin, C Sebban, ... Blood 101 (11), 4279-4284, 2003 | 716 | 2003 |
| Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial S Horwitz, OA O'Connor, B Pro, T Illidge, M Fanale, R Advani, NL Bartlett, ... The Lancet 393 (10168), 229-240, 2019 | 692 | 2019 |
| Treatment of older patients with mantle-cell lymphoma HC Kluin-Nelemans, E Hoster, O Hermine, J Walewski, M Trneny, ... New England Journal of Medicine 367 (6), 520-531, 2012 | 635 | 2012 |
| Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas C Gisselbrecht, P Gaulard, E Lepage, B Coiffier, J Brière, C Haioun, ... Blood, The Journal of the American Society of Hematology 92 (1), 76-82, 1998 | 632 | 1998 |
| Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87–2 protocol—a groupe d’Etude des lymphomes de l … C Haioun, E Lepage, C Gisselbrecht, G Salles, B Coiffier, P Brice, A Bosly, ... Journal of Clinical Oncology 18 (16), 3025-3030, 2000 | 573 | 2000 |
| Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial F Peyrade, F Jardin, C Thieblemont, A Thyss, JF Emile, S Castaigne, ... The Lancet Oncology 12 (5), 460-468, 2011 | 564 | 2011 |
| Phase III trial of consolidation therapy with yttrium-90–ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma F Morschhauser, J Radford, A Van Hoof, U Vitolo, P Soubeyran, H Tilly, ... Journal of Clinical Oncology 26 (32), 5156-5164, 2008 | 531 | 2008 |
| Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients K Belhadj, F Reyes, JP Farcet, H Tilly, C Bastard, R Angonin, E Deconinck, ... Blood 102 (13), 4261-4269, 2003 | 514 | 2003 |
| LAZ3, a novel zinc–finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas JP Kerckaert, C Deweindt, H Tilly, S Quief, G Lecocq, C Bastard Nature genetics 5 (1), 66-70, 1993 | 509 | 1993 |
| An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma TE Witzig, JM Vose, PL Zinzani, CB Reeder, R Buckstein, JA Polikoff, ... Annals of Oncology 22 (7), 1622-1627, 2011 | 486 | 2011 |
| ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma F Reyes, E Lepage, G Ganem, TJ Molina, P Brice, B Coiffier, P Morel, ... New England Journal of Medicine 352 (12), 1197-1205, 2005 | 449 | 2005 |
